Pharmaceutical

Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders

With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.

Nov 1, 2024 - 04:00
Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders
With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.
Read the original article

Tags:

Previous Article

Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions

Next Article

Bladder cancer diagnoses to top 300,000 in major markets by 2033

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Obesity impairs brain responses to nutrients, even after weight loss, study finds

Obesity impairs brain responses to nutrients, even afte...

Jun 12, 2023

Market cap upturn for top 20 biopharma companies with obesity drug successes in 2023

Market cap upturn for top 20 biopharma companies with o...

Mar 1, 2024

Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability

Opinion: STAT+: A California court is setting a dangero...

Feb 13, 2024